Articles » 2006 » July / August 2006 » Feature




Photo courtesy of Genzyme
Top 10 Biopharma Companies Report



Amgen continues to rule the Top 10 Biopharma rankings, but 2005 saw a couple of players make great strides. Genentech and Gilead continued to post huge gains (+46% each) on the strength of their oncology and HIV drugs, respectively.

Chiron also eked its way back into the billion-dollar ranks after its vaccine-manufacturing disaster in 2004, but it wasn’t enough to help the company stay independent; the company was bought by Novartis and will disappear from this chart next year.
—Gil Y. Roth
Editor
Contributors

Editor:    Gil Y. Roth
Associate Editor:    Kristin Brooks
Contributing Editor:    Derek B. Lowe

Top 10 Biopharmaceutical Companies

based on 2005 biopharma revenues
1  Amgen $12,022
2  Genentech $5,488
3  Serono $2,339
4  Biogen Idec $2,326
5  Gilead Sciences
 $1,809
6  Genzyme Corp.
 $1,773
7  MedImmune $1,221
8  Chiron Corp. $1,138
9  Millennium Pharmaceuticals
 $316
10  ImClone $221

2005 R&D Expenditures
1  Amgen $2,314
2  Genentech $1,262
3  Biogen Idec $747
4  Serono $594
5  Genzyme Corp.
 $503
6  Chiron Corp. $434
7  MedImmune $385
8  Millennium Pharmaceuticals
 $342
9  Gilead Sciences
 $278
10  ImClone $99


Note: In all Top Company profiles, dollar amounts are in millions.